Korean patients taking α1-adrenergic receptor antagonists show lower incidence of intraoperative floppy iris syndrome than western patients

被引:14
|
作者
Lim, Dong Hui [1 ]
Lee, Min Gyu [1 ]
Chung, Tae-Young [1 ]
Chung, Eui-Sang [1 ]
机构
[1] Sungkyunkwan Univ, Samsung Med Ctr, Dept Ophthalmol, Sch Med, Seoul 135710, South Korea
关键词
TAMSULOSIN; THYMOXAMINE; ALFUZOSIN; MYDRIASIS;
D O I
10.1136/bjophthalmol-2013-304135
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose To evaluate the incidence and clinical manifestations of intraoperative floppy iris syndrome (IFIS) according to iris alterations in Korean patients taking alpha 1-adrenergic receptor antagonists (alpha 1-ARAs). Methods This is a prospective observational study. Two surgeons performed cataract surgery in 758 eyes of 596 patients over a period of 12 months. Past medical history was reviewed, especially whether patients had been taking systemic alpha 1-ARAs. Ultrasound biomicroscopy was performed to measure the iris thickness of the dilator muscle region (DMR) at half the distance between the scleral spur and the pupillary margin. Pupil diameter was measured and the occurrence of IFIS was recorded. Measurements of the alpha 1-ARA group were compared with those of a control group matched for age and sex. Results IFIS occurred only in six eyes of four patients on systemic alpha 1-ARA medications (0.8%). Pupil diameter in the alpha 1-ARA medication group and the control group was not significantly different. The difference in mean DMR thickness in patients taking an alpha 1-ARA and in the control group was also not statistically significant (p=0.641). However, within the alpha 1-ARA population, the DMR thickness of IFIS cases was significantly lower than that of non-IFIS cases (p=0.013) Conclusions The overall incidence of IFIS was far lower in Korean patients than that reported for western patients. IFIS patients taking alpha 1-ARAs showed significantly greater iris DMR thinning than non-IFIS patients taking alpha 1-ARAs. Our findings indicate that the interaction between a1-ARAs and melanin, which results in iris DMR atrophy and IFIS, is less strong in Korean patients (with dark irises) than western patients.
引用
收藏
页码:479 / 483
页数:5
相关论文
共 18 条
  • [11] Preoperative use of atropine to prevent intraoperative floppy-iris syndrome in patients taking tamsulosin
    Bendel, Rick E.
    Phillips, Michael B.
    JOURNAL OF CATARACT AND REFRACTIVE SURGERY, 2006, 32 (10): : 1603 - 1605
  • [12] Alterations in Iris Structure and Pupil Size Related to Alpha-1 Adrenergic Receptor Antagonists Use: Implications for Floppy Iris Syndrome
    Tufan, Hasan Ali
    Gencer, Baran
    Kara, Selcuk
    Comez, Arzu Taskiran
    Kurt, Hasan Anil
    Alan, Cabir
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2013, 29 (04) : 410 - 413
  • [13] Evaluation of Patients Using Tamsulosin or Doxazosin for Lower Urinary Tract Symptoms for Development of Intraoperative Floppy Iris Syndrome
    Gokoe, Sabite Emine
    Gokce, Mehmet Ilker
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2015, 14 (04): : 251 - 253
  • [14] Sub-Tenon injection of 2% lidocaine prevents intra-operative floppy iris syndrome (IFIS) in male patients taking oral a-adrenergic antagonists
    Klysik, Anna
    Korzycka, Dorota
    ACTA OPHTHALMOLOGICA, 2014, 92 (06) : 535 - 540
  • [15] Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin—a UK-based comparison of incidence and complication rates
    Anjana Haridas
    Marina Syrimi
    Basel Al-Ahmar
    Melanie Hingorani
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2013, 251 : 1541 - 1545
  • [16] Intraoperative floppy iris syndrome (IFIS) in patients receiving tamsulosin or doxazosin-a UK-based comparison of incidence and complication rates
    Haridas, Anjana
    Syrimi, Marina
    Al-Ahmar, Basel
    Hingorani, Melanie
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2013, 251 (06) : 1541 - 1545
  • [17] The Use of α1-Adrenergic Receptor Antagonists in the Prevention of Adverse Outcomes of COVID-19 Infection in Obese Patients
    Fares, Auda
    Toprak, Resul
    Borrman, Dieter
    Ivester, Julius R.
    ADVANCES IN HUMAN BIOLOGY, 2022, 12 (03) : 329 - 332
  • [18] PATIENTS WITH MAFLD TAKING GLUCAGON LIKE PEPTIDE-1 RECEPTOR AGONISTS DO NOT HAVE HIGHER INCIDENCE FOR HEPATOBILIARY CANCER BUT HAVE LOWER OVERALL MORTALITY: A MULTI-CENTER ANALYSIS.
    Nieto, Luis M.
    Narvaez, Sharon
    Argueta, Pedro Palacios
    Martinez, John
    Davisson, Laura
    Vega, Kenneth J.
    GASTROENTEROLOGY, 2024, 166 (05) : S1559 - S1559